These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19857121)

  • 1. Production and characterization of monoclonal antibodies to human sclerostin.
    Craig TA; Sommer SL; Beito TG; Kumar R
    Hybridoma (Larchmt); 2009 Oct; 28(5):377-81. PubMed ID: 19857121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats.
    Feng G; Chang-Qing Z; Yi-Min C; Xiao-Lin L
    Int Immunopharmacol; 2015 Jan; 24(1):7-13. PubMed ID: 25479724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury.
    Roudier M; Li X; Niu QT; Pacheco E; Pretorius JK; Graham K; Yoon BR; Gong J; Warmington K; Ke HZ; Black RA; Hulme J; Babij P
    Arthritis Rheum; 2013 Mar; 65(3):721-31. PubMed ID: 23233270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on romosozumab : a humanized monoclonal antibody to sclerostin.
    Costa AG; Bilezikian JP; Lewiecki EM
    Expert Opin Biol Ther; 2014 May; 14(5):697-707. PubMed ID: 24665957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
    Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
    J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats.
    Suen PK; He YX; Chow DH; Huang L; Li C; Ke HZ; Ominsky MS; Qin L
    J Orthop Res; 2014 Aug; 32(8):997-1005. PubMed ID: 24782158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of sclerostin: emerging concepts.
    Drake MT; Farr JN
    Curr Opin Rheumatol; 2014 Jul; 26(4):447-52. PubMed ID: 24807403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
    Soen S
    Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-sclerostin antibodies].
    Okazaki R
    Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin antibody enhances bone formation in a rat model of distraction osteogenesis.
    McDonald MM; Morse A; Birke O; Yu NYC; Mikulec K; Peacock L; Schindeler A; Liu M; Ke HZ; Little DG
    J Orthop Res; 2018 Apr; 36(4):1106-1113. PubMed ID: 28884841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2011 Jan; 11(1):117-27. PubMed ID: 21114421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
    Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats.
    Suen PK; Zhu TY; Chow DH; Huang L; Zheng LZ; Qin L
    Sci Rep; 2015 Oct; 5():15632. PubMed ID: 26494536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
    Zhang D; Hu M; Chu T; Lin L; Wang J; Li X; Ke HZ; Qin YX
    Bone; 2016 Jun; 87():161-8. PubMed ID: 26868528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects.
    Yao Y; Kauffmann F; Maekawa S; Sarment LV; Sugai JV; Schmiedeler CA; Doherty EJ; Holdsworth G; Kostenuik PJ; Giannobile WV
    Sci Rep; 2020 Oct; 10(1):16217. PubMed ID: 33004873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis.
    Eddleston A; Marenzana M; Moore AR; Stephens P; Muzylak M; Marshall D; Robinson MK
    J Bone Miner Res; 2009 Oct; 24(10):1662-71. PubMed ID: 19419292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.